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ttp://dx.doi.org/10.1016/j.jmoldx.2014.11.005The ATP-binding cassette, subfamily C [CFTR/MRP], member 2 (ABCC2) gene is a member of the ATP-binding
cassette transporters and is involved in the transport of molecules across cellular membranes. Substrates
transported by ABCC2 include antiepileptics, statins, tenofovir, cisplatin, irinotecan, and carbamazepine.
Because of the pharmacogenomics implications, we developed a clinical laboratoryedeveloped assay to test
for seven variants in the ABCC2 gene: c.3563T>A (p.V1188E, rs17222723), c.1249G>A (p.V417I,
rs2273697), c.3972C>T (p.I1324I, rs3740066), c.2302C>T (p.R768W, rs56199535), c.2366C>T (p.S789F,
rs56220353), c.-24C>T (50UTR, rs717620), and c.4544G>A (p.C1515Y, rs8187710). During the validation
process, we noted several DNA samples, obtained from the Coriell Cell Repository, that contained both
c.3563T>A, c.4544G>A, and a third variant, suggesting that c.3563T>A and c.4544G>A are in cis on the
chromosome in some individuals. We obtained DNA samples from a trio (father, mother, and child), tested
their ABCC2 variants, and conﬁrmed that c.3563T>A and c.4544G>A were in cis on the same chromosome.
Here, we report a new haplotype in ABCC2. (J Mol Diagn 2015, 17: 201e205; http://dx.doi.org/10.1016/
j.jmoldx.2014.11.005)Supported by IGNITE project grant U01HG007762 (V.M.P., B.N.B.,
T.C.S., D.A.F., K.D.L., G.H.V.).
Disclosures: The Indiana University School of Medicine Pharmacoge-
nomics Laboratory is a fee-for-service clinical laboratory.Interindividual variation in drug response among patients
is well known and poses a serious challenge in medicine.
At present, there are a limited number of biomarkers that
can predict which group of patients will respond posi-
tively, which patients are nonresponders, and which will
experience adverse reactions for the same medication and
dose. Physicians often optimize dosage regimens for an
individual patient by a trial-and-error method, leading to
adverse drug reactions in some patients. In fact, adverse
reactions are found to occur in more than two million cases
annually in the United States and account for 100,000
deaths.1 Similarly, in a large prospective German study,
about 6% of new hospital admissions were due to adverse
drug reactions.2 This interindividual variability in drug
response could be due to multiple factors such as disease
determinants, genetic and environmental factors, variability
in drug target response (pharmacodynamic response) or
idiosyncratic response. These factors affect drug absorp-
tion, distribution, metabolism, and excretion.3 Thus, an
understanding of the variability of drug response, especiallystigative Pathology
.genetic variability, in efﬁcacy and toxicity of medications
may provide safer and more effective drug therapy.
The ATP-binding cassette, subfamily C (CFTR/MRP),
member 2 (ABCC2) gene is a member of the ATP-binding
cassette transporters. ABCC2 is located on the apical mem-
brane and is important in detoxiﬁcation and chemoprotection.
It transports a wide range of compounds, especially conjugates
of lipophilic substances with glutathione, glucuronate, and
sulfate, which are phase II products of biotransformation.
ABCC2 can also transport uncharged compounds in cotrans-
port with glutathione, and thus modulates the pharmacoki-
netics of many drugs.4 The ABCC subfamily contains 12 full
transporters that perform functions in ion transport, toxin
secretion, and signal transduction. This protein is a member of
theMRP subfamily, which is involved inmultidrug resistance,
Table 1 Allelic Sequences for TaqMan Reagents
dbSNP# Sequence
rs3740066 50-TCCTCAGAGGGATCACTTGTGACAT[C/T]
GGTAGCATGGAGAAGGTAGGTGGAG-30
rs8187710 50-CTAGACAACGGGAAGATTATAGAGT[A/G]
CGGCAGCCCTGAAGAACTGCTACAA-30
rs56199535 50-AAATCTTAGTGGGGGTCAGAAGCAG[C/T]
GGATCAGCCTGGCCAGAGCTACCTA-30
rs56220353 50-ATCTATCTTCTAGATGACCCCCTGT[C/T]
TGCAGTGGATGCTCATGTAGGAAAA-30
rs2273697 50-CAACTTGGCCAGGAAGGAGTACACC[A/G]
TTGGAGAAACAGTGAACCTGATGTC-30
rs17222723 50-CAGCGATTTCTGAAACACAATGAGG[A/T]
GAGGATTGACACCAACCAGAAATGT-30
rs717620 50-ACAATCATATTAATAGAAGAGTCTT[C/T]
GTTCCAGACGCAGTCCAGGAATCAT-30
Pratt et aland is expressed in the canalicular (apical) part of the hepa-
tocyte and functions in biliary transport. It is additionally
present in the kidneys, intestines, and placenta (National
Cancer Biotechnology Institute, http://www.ncbi.nlm.nih.gov/
IEB/Research/Acembly/av.cgi?dbZhuman&cZGene&lZ
ABCC2, last accessed October 17, 2014). Substrates trans-
ported by ABCC2 include antiepileptics, statins, tenofovir,
cisplatin, irinotecan, and carbamazepine (the Pharmacoge-
nomics Knowledgebase, http://www.pharmgkb.org/gene/
PA116, last accessed March 13, 2014). An example of
deleterious effects of DNA variants within the ABCC sub-
family is cystic ﬁbrosis, which is an inherited multisystem
disorder characterized by abnormalities in exocrine gland
function consequent to loss of function of the cystic ﬁbrosis
transmembrane conductance regulator (CFTR) transporter.
Similar to cystic ﬁbrosis, defects in the ABCC2 gene have
been shown to cause Dubin-Johnson syndrome.5e9
Dubin-Johnson syndrome is an autosomal recessive disorder
characterized by jaundice. In addition to hyperbilirubinemia,
affected individuals have an increase in the urinary excretion of
coproporphyrin isomer I, deposition ofmelanin-like pigment in
hepatocytes, and prolonged retention of sulfobromophthalein,
but otherwise normal liver function (Online Mendelian Inher-
itance in Man, http://omim.org/entry/237500, last accessed
October 31, 2014).
Because of the pharmacogenomic implications, we devel-
oped a clinical laboratory assay to test for seven variants in
the ABCC2 gene: c.3563T>A (p.V1188E, rs17222723),
c.1249G>A (p.V417I, rs2273697), c.3972C>T (p.I1324I,
rs3740066), c.2302C>T (p.R768W, rs56199535), c.2366C>T
(p.S789F, rs56220353), c.-24C>T (50UTR, rs717620), and
c.4544G>A (p.C1515Y, rs8187710). During the analytical
validation process, we noted several DNA samples obtained
from the Coriell Cell Repository (Camden, NJ) that contained
both c.3563T>A (p.V1188E, rs17222723), c.4544G>A
(p.C1515Y, rs8187710), and a third variant, suggesting that
c.3563T>A and c.4544G>A are in cis in some of these
individuals.
Materials and Methods
Samples
Fifty-one reference DNA samples were selected and ob-
tained from the Coriell Cell Repository, based on partial
genotypic information.10 An additional 50 anonymous
DNA samples were obtained from the Indiana BioBank
(Indianapolis, IN). Three anonymized whole-blood and
matched saliva samples from unrelated individuals were
also obtained.
DNA Extraction
DNA was extracted from the whole blood and saliva (DNA
Genotek, Toronto, ON, Canada) using the Qiagen QiAMP
reagents (Valencia, CA) according to the manufacturer’s202instructions. Approximately 1 mg of DNA was extracted
from the blood and saliva samples, with an average con-
centration of approximately 30 ng/mL.
ABCC2 Genotyping
Seven variants were chosen for the genotyping assay based on
commercial reagents and positive reference material availabil-
ity: c.1249G>A (p.V417I; rs2273697), c.3972C>T (p.I1324I;
rs3740066), c.-24C>T (50UTR; rs717620), c.3563T>A
(p.V1188E; rs17222723), c.4544G>A (p.C1515Y; rs818
7710), c.2302C>T (p.R768W; rs56199535), and c.2366C>T
(p.S789F; rs56220353). DNA was ampliﬁed in singlicate by
real-time PCR on the LifeTech QuantStudio 12K Flex software
version 1.2.2 (Grand Island, NY) and subjected to TaqMan
allele discrimination using commercially available LifeTech
reagents in a custom-designed open array (Table 1).
Statistical Analysis
Pairwise linkage disequilibrium coefﬁcients, D0 and r2, were
computed from the observed genotype data for the variants of
interest. Calculations were performed using the Haploview
software version 4.2 (Broad Institute, Cambridge, MA).11
Minor allele frequency and the Hardy-Weinberg test statis-
tic were also computed for each variant using Haploview
from the same genotype data.
Results
One hundred four DNA samples were genotyped for
seven variants in the ABCC2 gene. We observed ﬁve
samples in which c.3563T>A and c.4544G>A occurred with
a third variant [ie, c.3972C>T (p.I1324I; rs3740066),
c.2302C>T (p.R768W; rs56199535), c.1249G>A (p.V417I;
rs2273697)]. We noted that c.3563T>A and c.4544G>A
could also occur independently. One sample (1%) was het-
erozygous for c.3563T>A, 6 samples (6%) were heterozygous
for c.4544G>A, and 11 samples (11%) were compoundjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 2 New Haplotypes for ABCC2
ABCC2
Haplotypes
rs1885301 rs2804402 rs717620 rs2273697
Intron26-34T>C
rs17222723 rs3740066 rs8187710
c.-1549G>A c.-1019A>G
c.-24C>T
(50UTR)
c.1249G>A
(p.V417I)
c.3563T>A
(p.V1188E)
c.3972C>T
(p.I1324I)
c.4544G>A
(p.C1515Y)
H1 G A C G T T C G
H2 A G T G T T
H3 G A C A T C
H4 A G C G T T
H5 A G C G T C
H6 A G C G C C
H7 G A C G T T
H8 G A C G C C
H9 A G T G T C
H10 A A C G T C
H11 G A C A T T
H12 A A C G C C
H13 C A T
H14 T A C
H15 T A T
H16 C G A C
H17 C A A C
H18 C G T C A
H19 C G A C A
Haplotypes in bold are the new haplotypes described within this paper. The minor allele is denoted in italics.
New Haplotype for ABCC2 Geneheterozygous (Table 2). No deviation from Hardy-Weinberg
equilibrium was observed for either c.3563T>A or
c.4544G>A among the individuals genotyped (P > 0.5). On
the basis of the genotypes observed in our samples, the
c.3563T>A and c.4544G>A loci are in high linkage
disequilibrium (D0 Z 0.91; r2 Z 0.58), which is consistent
with their close physical proximity within ABCC2 (15.3 kb
apart) and their similar minor allele frequencies (6.1% and
8.5%, respectively).
A trio of samples were obtained (mother, father,
offspring) and genotyped for ABCC2 to resolve phasing of
c.3563T>A and c.4544G>A. The father was a compound
homozygote for c.3563T>A and c.4544G>A, whereas the
mother and offspring were compound heterozygotes forFigure 1 The father (square) is compound homozygous for c.3563T>A
and c.4544G>A, whereas the mother (circle) and offspring (diamond) are
compound heterozygous for both c.3563T>A and c.4544G>A. NVD, no
variant detected.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgboth variants. These results conﬁrmed that c.3563T>A and
c.4544G>A are in cis within this region of high linkage
disequilibrium (Figure 1) in this trio, and that the haplotype
containing both variant alleles is indeed present in the
population.Discussion
ABCC2 facilitates ion transport, toxin secretion, and signal
transduction. As such, we developed a laboratory test for
clinically relevant ABCC2 variants for pharmacogenomic
testing. For well-established tests, there is consensus as to
which variants should be present in a clinical assay. For
pharmacogenetic assays where the ﬁeld is continuing to
evolve, there is currently lack of consensus or standardization
as to which variants should be assayed for many, if not most
genes. The Clinical Pharmacogenetics Implementation
Consortium (CPIC) evaluates the evidence of each variant, but
does not provide a genotyping minimum standard as that is
outside the purview of their charge. At this time, there are no
CPIC guidelines that support ABCC2 testing. Thus, we chose
the variants in our clinical assay based on information available
for each variant, the availability of commercial reagents, and
reference materials.
We reviewed the ABCC2 haplotypes that had been
reported in the literature.12e14 The current curated database
of haplotypes for ABCC2 in The Pharmacogenomics
Knowledgebase (http://www.pharmgkb.org/gene/PA116, last
accessed May 1, 2014) demonstrates redundancy and lack of
consensus mentioned above. For example, H11 and H13 are
positive for the same two single nucleotide polymorphisms,203
Table 3 Proposed Allele Nomenclature for ABCC2 Haplotypes
Allele Nucleotide changesy (reference NM_000392.3) Legacy name Effects
ABCC2*1 No variant detected H1
ABCC2*2 c.-1549G>A, c.-1019A>G, c.-24C>T, c.3972C>T H2 p.I1324I
ABCC2*3A c.1249G>A H3 p.V417I
ABCC2*3B c.1249G>A, c.3972C>T H11, H13 p.V417I, p.I1324I
ABCC2*3C c.-24C>T, c.1249G>A H14 p.V417I
ABCC2*3D c.-24C>T, c.1249G>A, c.3972C>T H15 p.V417I, p.I1324I
ABCC2*4 c.-1549G>A, c.-1019A>G, c.3972C>T H4 p.I1324I
ABCC2*5 c.-1549G>A, c.-1019A>G H5
ABCC2*6 c.-1549G>A, c.-1019A>G, intron26-34T>C H6
ABCC2*7 c.3972C>T H7 p.I1324I
ABCC2*8 intron26-34T>C H8
ABCC2*9 c.-1549G>A, c.-1019A>G, c.-24C>T H9
ABCC2*10 c.-1549G>A H10
ABCC2*11 c.-1549G>A, intron26-34T>C H12
ABCC2*12 c.3563T>A H16 p.V1188E
ABCC2*13 c.1249G>A, c.3563T>A H17 p.V417I, p.V1188E
ABCC2*14 c.4544G>A H18 (new) p.C1515Y
ABCC2*15 c.3563T>A, c.4544G>A H19 (new) p.V1188E, p.C1515Y
ABCC2*16 c.2302C>T p.R768W
ABCC2*17 c.2366C>T p.S789F
The deﬁning variant(s) are in bold.
yReference NM_000392.3, http://www.ncbi.nlm.nih.gov/nuccore/NM_000392.3.
Pratt et alc 1249G>A and c.3972C>T. Because the two articles
referenced for these haplotypes do not completely overlap as
to the variants genotyped (Table 2), the curators have chosen
to keep them separate with regard to the annotated associa-
tions reported in the two prior papers.
Often, the haplotypes are inferred from variant genotyping
and not always conﬁrmed in family studies. The two common
variants in ABCC2 on which we focus in this report
(c.3563T>A and c.4544G>A) are reported to be associated
with impaired drug transport and adverse drug reactions.15,16
Although not speciﬁcally noted nor conﬁrmed, both studies
appear to have inferred a haplotype containing c.3563T>A
and c.4544G>A in cis in a small number of subjects. We
directly conﬁrmed the cis phasing of these variants in a trio
informative for phase at both loci. Through our studies, we
also noted that c.3563T>A and c.4544G>A could occur
independently as well.
Interestingly, two other ABCC2 variants, rs717620
(c.-24C>T) and rs3740066 (c.3972C>T), have been reported
to be within the same haplotype (ie, H2 and H15; https://www.
pharmgkb.org/gene/PA116, last accessed May 1, 2014). Soo-
koian et al16 reported or inferred several haplotypes not in
agreement with pharmgkb.org (https://www.pharmgkb.org/
gene/PA116, accessed May 1, 2014), including an H7 that
has both the c.3563T>A and c.4544G>A variants. In addition,
the authors had the reference haplotype as H3, where standard
convention would have the reference sequence as H1.
Pharmacogenetic sequence variants are often designated by a
nomenclature of star (*) alleles, where *1 is designated as
normal (commonly referred to as wild type), and subsequent
variant alleles are numbered in the order that they are described.204Within each star allele designation, variants that are in cis with
the deﬁning single nucleotide polymorphism create subfamilies
that are designated alphabetically in the order that they are
described (eg, *2A, *2B, *2C). The use of the star allele
nomenclature is considered by some to be confusing and
outdated; but because pharmacogenomic testing often involves
multiple variants in a haplotype, rather than a single mutation
(similar to the histocompatibility leukocyte antigen, HLA,
nomenclature system), its usepersists today.Because of the lack
of clarity in the current haplotypes,we propose thatABCC2 also
be described using the star allele nomenclature. We have made
an attempt to translate the haplotype information to ABCC2 star
alleles (Table 3). The functionality ofmany of the variants is not
known in vitro or in vivo. Also, where functionality has been
studied, the data have been conﬂicting.17e21
In the star allele nomenclature that we are proposing, unique
alleles were assigned where there were missense mutations.
Several haplotypes involving p.V417I were grouped together
in single star alleles under this nomenclature; although this
change is a missense mutation, valine has an aliphatic side
chain as does isoleucine. Substitutions of valine for isoleucine
are considered homologous substitutions and usually are not
expected to alter protein function. It was more difﬁcult to
classify changes in the promoter region, as well as synony-
mous DNA variants that did not result in changes in amino
acid sequence. Star alleles were tentatively assigned to each
unique haplotype (Table 3). Functional studies will be needed
to determinewhether the unique haplotypes should be grouped
together as suballeles.
Pharmacogenomic testing incorporates molecular typing
of genetic variants to help predict human variability in drugjmd.amjpathol.org - The Journal of Molecular Diagnostics
New Haplotype for ABCC2 Generesponse. There are a considerable number of poly-
morphisms in many of the human genes associated with
pharmacokinetics or pharmacodynamics of exogenous
drugs. Here, we report and conﬁrm a new haplotype in
ABCC2 and propose a new star allele nomenclature.
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